NGS-DRIVEN MUTATION PROFILING IN BREAST CANCER: BRIDGING THE GAP BETWEEN REAL-WORLD DATA AND PERSONALIZED THERAPY

Next-generation sequencing (NGS) has emerged as a revolutionary weapon in oncology, particularly in breast cancer, enabling precise mutant profiles and the evolution of individualized treatment systems. NGS-based mutant profiling in breast cancer, contributing to the development of a better understanding of familial variations and their results in clinical practice. The NGS makes it possible to call multiple genetic variations, including the well-known BRCA1/2 gene, as well as a fresh variation that may influence the curative response. Despite its constancy, there are still several impediments to NGS integration into routine clinical practice, including data interpretation, cost, ease of use, and insufficient standard protocols. It is necessary to validate NGS results and translate them into capable, personalized treatment, hands-on statistics, and clinical trials. Reverence must also be accorded to the fair results of family testing, in particular about incidental consequences. To ensure that all patients benefit from the personalized therapy, the future of NGS in breast cancer lies in exultant these problems and improving productivity. NGS is capable of redefining breast cancer medicines, providing a powerful, target therapy based on human characteristics.